TARGET-seq genotyped single-cell RNA sequencing of hematopoietic stem cells and megakaryocyte-erythroid progenitor cells from a dual SF3B1-mutant MDS-RS patient and 3 healthy donors TARGET-seq genotyped single-cell RNA sequencing of hematopoietic stem cells and megakaryocyte-erythroid progenitor cells from a dual SF3B1-mutant MDS-RS patient and 3 healthy donors 2023-223-1 https://doi.org/10.48723/d7s9-6336 Swedish National Data Service Svensk nationell datatjänst Landing page TARGET-seq genotyped single-cell RNA sequencing of hematopoietic stem cells and megakaryocyte-erythroid progenitor cells from a dual SF3B1-mutant MDS-RS patient and 3 healthy donors TARGET-seq genotyped single-cell RNA sequencing of hematopoietic stem cells and megakaryocyte-erythroid progenitor cells from a dual SF3B1-mutant MDS-RS patient and 3 healthy donors 2023-223-1 https://doi.org/10.48723/d7s9-6336 10.1016/j.bneo.2024.100011 Moura, Pedro Luis Moura, Pedro Luis Hellström-Lindberg, Eva Hellström-Lindberg, Eva 21 0340 21 0340 2021-01404_VR 2021-01404_VR 2017.0359 2017.0359 19 0200 19 0200 Swedish National Data Service Svensk nationell datatjänst Landing page This dataset consists of TARGETseq (genotype-targeted plate-based SmartSeq2) single-cell RNA sequencing data of purified hematopoietic stem cells (HSC) and megakaryocyte-erythroid progenitors (MEP) from the bone marrow of a dual SF3B1-mutant MDS-RS patient (Patient 1 in the associated publication) over 2 timepoints (39 months post-diagnosis, with dominant SF3B1-N626D, and 118 months post-diagnosis, with dominant SF3B1-K666N); and purified HSC/MEP from the bone marrow of three healthy donors. The objective of this data collection was to assess the molecular characteristics that increase fitness in SF3B1-mutant HSC as compared to normal HSC. The dataset is approximately 187 GB and includes the file types: zip, xlsx, bam, bam.bai, rds. Denna datauppsättning består av TARGETseq (genotypriktad plattbaserad SmartSeq2) RNA-sekvenseringsdata från renade hematopoetiska stamceller (HSC) och megakaryocyt-erytroida progenitorer (MEP) från benmärgen hos en dubbel SF3B1-mutant MDS-RS patient vid två tillfällen poäng (39 månader efter diagnos och 118 månader efter diagnos); och renad benmärg HSC/MEP från tre friska donatorer. Syftet med denna datainsamling var att bedöma de molekylära egenskaperna som ökar "fitness" i SF3B1-mutant HSC jämfört med normal HSC. Se den engelska beskrivningen för mer information. CellsCells CellerCeller Patients with Myelodysplastic neoplasms with ring sideroblasts (MDS-RS) Patienter med myelodysplastisk syndrom med ringsideroblaster (MDS-RS) Numeric Other Time series: DiscreteTime series: Discrete Tidsserie: DiskretTidsserie: Diskret The data in this dataset comes from 1 dual SF3B1mt MDS-RS patient and 3 healthy donors. Bone marrow (BM) samples were collected from 2 dual SF3B1mt MDS-RS patients (Patient 1: N626D, K666N; Patient 2: K700E, K666N) evaluated at Karolinska University Hospital, Sweden. Diagnostic procedures were performed according to the European LeukemiaNet recommendation and WHO classification for myeloid neoplasms. Mutational status was evaluated at the clinic through panel sequencing for the most common myeloid mutations. Additional samples were collected from a total of 4 healthy NBM donors for control purposes. All source material was provided with written informed consent for research use, given in accordance with the Declaration of Helsinki, and the study was approved by the Ethics Research Committee at Karolinska Institutet.The data in this dataset comes from 1 dual SF3B1mt MDS-RS patient and 3 healthy donors. Bone marrow (BM) samples were collected from 2 dual SF3B1mt MDS-RS patients (Patient 1: N626D, K666N; Patient 2: K700E, K666N) evaluated at Karolinska University Hospital, Sweden. Diagnostic procedures were performed according to the European LeukemiaNet recommendation and WHO classification for myeloid neoplasms. Mutational status was evaluated at the clinic through panel sequencing for the most common myeloid mutations. Additional samples were collected from a total of 4 healthy NBM donors for control purposes. All source material was provided with written informed consent for research use, given in accordance with the Declaration of Helsinki, and the study was approved by the Ethics Research Committee at Karolinska Institutet. Probability: Simple randomProbability: Simple random Sannolikhetsurval: obundet slumpmässigt urvalSannolikhetsurval: obundet slumpmässigt urval Non-probability: AvailabilityNon-probability: Availability Icke-sannolikhetsurval: tillgänglighetsurvalIcke-sannolikhetsurval: tillgänglighetsurval Mixed probability and non-probabilityMixed probability and non-probability Blandat sannolikhets- och icke-sannolikhetsurvalBlandat sannolikhets- och icke-sannolikhetsurval Access to data through SND. Access to data is restricted. Åtkomst till data via SND. Tillgång till data är begränsad. restrictedAccess Pedro Luis Moura, Yasuhito Nannya, Affaf Aliouat, Isabel Juliana Hofman, Teresa Mortera Blanco, Tetsuichi Yoshizato, Ryunosuke Saiki, Masahiro M Nakagawa, Maria Creignou, Ann-Charlotte Björklund, Gunilla Walldin, Indira Barbosa, Monika Jansson, Francesca Grasso, Edda M Elvarsdottir, Petter S Woll, Sten Eirik W Jacobsen, Seishi Ogawa, Eva Hellström-Lindberg, Competition of dual SF3B1mt clones in MDS-RS is associated with distinct RNA mis-splicing in hematopoietic stem cells, Blood Neoplasia, 2024,100011, ISSN 2950-3280, https://doi.org/10.1016/j.bneo.2024.100011. Pedro Luis Moura, Yasuhito Nannya, Affaf Aliouat, Isabel Juliana Hofman, Teresa Mortera Blanco, Tetsuichi Yoshizato, Ryunosuke Saiki, Masahiro M Nakagawa, Maria Creignou, Ann-Charlotte Björklund, Gunilla Walldin, Indira Barbosa, Monika Jansson, Francesca Grasso, Edda M Elvarsdottir, Petter S Woll, Sten Eirik W Jacobsen, Seishi Ogawa, Eva Hellström-Lindberg, Competition of dual SF3B1mt clones in MDS-RS is associated with distinct RNA mis-splicing in hematopoietic stem cells, Blood Neoplasia, 2024,100011, ISSN 2950-3280, https://doi.org/10.1016/j.bneo.2024.100011. 10.1016/j.bneo.2024.100011 2024